<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332017000100034</article-id>
<article-id pub-id-type="doi">10.1016/j.rccar.2016.02.005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Isquemia miocárdica: conceptos básicos, diagnóstico e implicaciones clínicas. Tercera parte]]></article-title>
<article-title xml:lang="en"><![CDATA[Myocardial ischemia: basic concepts, diagnosis and clinical implications. Part three]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[Pedro R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Portillo]]></surname>
<given-names><![CDATA[Juan H. del]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Icahn School of Medicine at Mount Sinai  ]]></institution>
<addr-line><![CDATA[New York ]]></addr-line>
<country>USA</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Santa Fe de Bogotá  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2017</year>
</pub-date>
<volume>24</volume>
<numero>1</numero>
<fpage>34</fpage>
<lpage>39</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332017000100034&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332017000100034&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332017000100034&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El término «cardiopatía isquémica» se refiere a la disfunción del ventrículo izquierdo secundaria a infarto del miocardio, miocardio isquémico viable o enfermedad coronaria severa documentada por arteriografía coronaria, la cual tiene un pobre pronóstico, con una supervivencia del 45% a 5 años. El tratamiento de la cardiopatía isquémica involucra la estimación de la viabilidad en el miocardio afectado para determinar si la revascularización puede generar una remodelación positiva que mejore la función del ventrículo izquierdo. Existen cuatro modalidades básicas usadas en la práctica clínica para calcular la viabilidad miocárdica: tomografía de emisión simple de positrones, tomografía por emisión de positrones, ecocardiograma estrés y resonancia magnética cardiaca. Hoy en día hay estudios que demuestran que la terapia médica mejora la función del ventrículo izquierdo en la cardiopatía isquémica, independiente de la presencia o no de viabilidad o de la revascularización miocárdica; por tanto es posible que otros factores como la cantidad de remodelado, los volúmenes del ventrículo izquierdo, la insuficiencia mitral y la fracción de eyección puedan afectar también los desenlaces. Se requiere definir de manera clara los estadios del remodelado ventricular izquierdo en los cuales la presencia de viabilidad es benéfica y las etapas en las que el remodelado es reversible con la revascularización miocárdica. En cuanto a los métodos para determinar la viabilidad, la resonancia magnética parece dar más respuestas al respecto, ya que puede aportar información adicional relacionada con dimensiones del ventrículo izquierdo, fracción de eyección, fibrosis miocárdica y anormalidades valvulares.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The term myocardial ischemia refers to a left ventricular dysfunction secondary to a myocardial infarction, viable ischemic myocardium or sever coronary disease documented by means of a coronary angiography, which has a poor prognosis, with five-year survival rate of 45%. Management of myocardial ischemia involves estimating viability of the affected myocardium in order to determine whether revascularization can generate a positive remodelling that improves left ventricle functioning. Four different basic modalities are used in clinical practice to assess myocardial viability: single-photon emission computed tomography, positron emission tomography, stress echocardiogram and cardiac magnetic resonance. Nowadays there are studies that have shown medical therapy improves left ventricle function in ischemic heart disease, regardless of the presence or not of the viability or the myocardial revascularization; therefore, it is possible that other factors such as the amount of remodelling, the left ventricle volumes, mitral insufficiency and ejection fraction could also afffect the outcomes. A clear definition of the left ventricle remodelling states where the presence of viability is beneficial and the stages where the remodelling is reversible with myocardial revascularization is required. With regards to methods for assessing viability, magnetic resonance seems to provide more answers, as it can give additional information related to the dimensions of the left ventricle, ejection fraction, myocardial fibrosis and valvular abnormalities.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Enfermedad coronaria]]></kwd>
<kwd lng="es"><![CDATA[Isquemia]]></kwd>
<kwd lng="es"><![CDATA[Cardiopatía isquémica]]></kwd>
<kwd lng="es"><![CDATA[Hibernación]]></kwd>
<kwd lng="es"><![CDATA[Flujo sanguíneo]]></kwd>
<kwd lng="en"><![CDATA[Coronary disease]]></kwd>
<kwd lng="en"><![CDATA[Ischemia]]></kwd>
<kwd lng="en"><![CDATA[Ischemic cardiac pathology]]></kwd>
<kwd lng="en"><![CDATA[Hibernation]]></kwd>
<kwd lng="en"><![CDATA[Blood Flow]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A standardized definition of ischemic cardiomyopathy for use in clinical research]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Felker]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[O'Connor CM]]></surname>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2002</year>
<volume>39</volume>
<page-range>210-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Risk factors for congestive heart failure in US men and women NHANES I epidemiologic follow-up study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ogden]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Bazzano]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Vupputuri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Loria]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Whelton]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Intern Med]]></source>
<year>2001</year>
<volume>161</volume>
<page-range>996-1002</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction a meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allman]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hachamovitch]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Udelson]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2002</year>
<volume>39</volume>
<page-range>1151-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Desideri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cortigiani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Christen]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Coscarelli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gregori]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zanco]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2005</year>
<volume>46</volume>
<page-range>1264-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pagley]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Beller]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Watson]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Gimple]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
<name>
<surname><![CDATA[Ragosta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>1997</year>
<volume>96</volume>
<page-range>793-800</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Reversibility of cardiac wall-motion abnormalities predicted by positron tomography]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tillisch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brunken]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Marshall]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Schwaiger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mandelkern]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Phelps]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>1986</year>
<volume>314</volume>
<page-range>884-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Predicting benefit from revascularization in patients with ischemic heart failure imaging of myocardial ischemia and viability]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buckley]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Di Carli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2011</year>
<volume>123</volume>
<page-range>444-50</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stunning, hibernation, and assessment of myocardial viability]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camici]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Prasad]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Rimoldi]]></surname>
<given-names><![CDATA[OE]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2008</year>
<volume>117</volume>
<page-range>103-14</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sequential (201) Tl imaging and dobutamine echocardiography to enhance accuracy of predicting improved left ventricular ejection fraction after revascularization]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bax]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maddahi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Poldermans]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Elhendy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cornel]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Boersma]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[J Nucl Med]]></source>
<year>2002</year>
<volume>43</volume>
<page-range>795-802</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Preoperative comparison of different noninvasive strategies for predicting improvement in left ventricular function after coronary artery bypass grafting]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bax]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maddahi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Poldermans]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Elhendy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schinkel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Boersma]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol]]></source>
<year>2003</year>
<volume>92</volume>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Incremental value of strain rate analysis as an adjunct to wall-motion scoring for assessment of myocardial viability by dobutamine echocardiography a follow-up study after revascularization]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanekom]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jenkins]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jeffries]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Case]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mundy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hawley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2005</year>
<volume>112</volume>
<page-range>3892-900</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rafael]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Simonetti]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2000</year>
<volume>343</volume>
<page-range>1445-53</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of myocardial revascularisation on left ventricular systolic function in patients with and without viable myocardium should non-viable segments be revascularised?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stipac]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Stankovic]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Vidakovic]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Putnikovic]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ilic]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Milicic]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Heart]]></source>
<year>2013</year>
<volume>99</volume>
<page-range>1749-54</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Coronary-artery bypass surgery in patients with left ventricular dysfunction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velazquez]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Deja]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sopko]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Marchenko]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<page-range>1607-16</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myocardial viability and survival in ischemic left ventricular dysfunction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Holly]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Binkley]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Desvigne- Nickens]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<page-range>1617-25</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial) randomised controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[JGF]]></given-names>
</name>
<name>
<surname><![CDATA[Pennell]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Coats]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Macfarlane]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2003</year>
<volume>362</volume>
<page-range>14-21</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seghatol]]></surname>
<given-names><![CDATA[FF]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Diluzio]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bello]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Cotts]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol]]></source>
<year>2004</year>
<volume>93</volume>
<page-range>854-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Survival after myocardial revascularization for ischemic cardiomyopathy a prospective ten-year follow-up study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hare]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Raman]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Horowitz]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<source><![CDATA[J Thorac Cardiovasc Surg]]></source>
<year>2003</year>
<volume>126</volume>
<page-range>1320-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerber]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Rousseau]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction impact of revascularization therapy]]></article-title>
<collab>le Polain de Waroux J-B.Pouleur A-C.Phlips T</collab>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2012</year>
<volume>59</volume>
<page-range>825-35</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
